See for yourself
VBL Therapeutics is using its unique scientific platforms and drug development capabilities to fight psoriasis, rheumatoid arthritis and other serious chronic immune-inflammatory diseases, as well as cancer. Both are sometimes life-threatening diseases inadequately addressed by current therapies.
Discover our platforms
VBL Therapeutics pioneered the Lecinoxoid class of oral anti-inflammatory agents, currently in a Phase 2 clinical trial for the treatment of psoriasis. In addition, we have developed an innovative, proprietary platform technology, VTS™ (Vascular Targeting System), which enables control of gene expression to areas in which angiogenesis is taking place to either promote or destroy newly formed blood vessels. We have used this technology to develop promising therapeutic compounds for cancer and ischemic diseases.
Find out more about the Lecinoxoid Platform Technology
In the clinic
Our first-in-class compound for the treatment of patients with psoriasis, VB-201, is currently in Phase 2 clinical trials. VBL is also entering Phase 2 clinical development with VB-111, our lead oncology drug candidate, which has already completed a Phase 1/2 trial in patients with cancer.